Final Year MD/PhD Student Zachary Walsh Receives the Weintraub Graduate Student Award

The Harold M. Weintraub Graduate Student Award is among the highest honors in biomedical graduate education. This year, it goes to Zachary Walsh, whose genome-engineering research is already changing outcomes for patients with rare immune disorders and cancer.

Zachary H. Walsh, a final-year MD-PhD candidate in the Department of Medicine, has been named a recipient of the Harold M. Weintraub Graduate Student Award. Presented by Fred Hutchinson Cancer Center, the award recognizes PhD students who demonstrate exceptional innovation and meaningful contributions to human health. Walsh is Columbia's first Weintraub honoree in several years and will be recognized at the annual symposium on May 1, 2026, in Seattle.

Working in the laboratory of Benjamin Izar, MD, PhD, Walsh's research focuses on understanding how genetic variation shapes immune cell behavior in rare immune disorders and cancer. He developed scalable CRISPR base-editing platforms to systematically engineer and test tens of thousands of genetic variants in primary immune cells, enabling his team to distinguish pathogenic variants from benign ones and trace precisely how they alter immune signaling. This work has already led to the molecular diagnosis and initiation of targeted therapy for a patient with a rare genetic immune disorder. He has applied the same platform to cancer immunotherapy, augmenting CAR-T therapy for leukemia and TCR-based T cell therapy for melanoma in preclinical models.

IN HIS OWN WORDS

"The Weintraub Award is an incredible honor and a reflection of the incomparable mentorship and collaborative environment in the Izar group that have shaped my physician-scientist training. Many patients suffer and live with uncertainty because we can't yet interpret and treat the genetic variants driving their disease. This recognition motivates me to continue developing approaches that translate genomic insight into faster diagnoses, improved therapies, and better outcomes for these patients." -- Zachary H. Walsh, MD-PhD Candidate, Izar Laboratory, CUIMC

FROM HIS MENTOR

"The Weintraub Award is a prestigious and fitting recognition of Zach's accomplishments and potential. Zach has mastered the complexities of genome-engineering to solve long-standing questions at the interface of human genetics and immunology. Watching his work evolve from an ambitious idea to landmark studies has been a highlight of my time as a mentor. He is more than a brilliant researcher; he is a visionary scientist who is already shaping the future of genomic medicine." -- Benjamin Izar, MD, PhD, Principal Investigator, Izar Laboratory, Department of Medicine, CUIMC

SELECTED PUBLICATIONS

Reclassifying genetic variants to improve diagnosis and treatment for patients with rare genetic immune disorders. Cell. https://www.cell.com/cell/abstract/S0092-8674(25)00624-5

Harnessing precision genome engineering to augment T cell-based therapies for melanoma and leukemia. Nature Biotechnology. https://www.nature.com/articles/s41587-024-02235-x